PURPOSE:Downstaging (DS) of rectal cancers is achieved in approximately 45% of patients with neoadjuvant fluorouracil (FU) -based chemoradiotherapy (CRT). Polymorphisms in the thymidylate synthase gene (TYMS) had previously defined two risk groups associated with disparate tumor DS rates (60% v 22%). We conducted a prospective single-institution phase II study using TYMS genotyping to direct neoadjuvant CRT for patients with rectal cancer. PATIENTS AND METHODS: Patients with T3/T4, N0-2, M0-1 rectal adenocarcinoma were evaluated for germline TYMS genotyping. Patients with TYMS *2/*2, *2/*3, or *2/*4 (good risk) were treated with standard chemoradiotherapy using infusional FU at 225 mg/m²/d. Patients with TYMS *3/*3 or *3/*4 (poor risk) were treated with FU/RT plus weekly intravenous irinotecan at 50 mg/m². The primary end point was pathologic DS. Secondary end points included complete tumor response (ypT0), toxicity, recurrence rates, and overall survival. RESULTS: Overall, 135 patients were enrolled, of whom 27.4% (37 of 135) were considered poor risk. The prespecified statistical goals were achieved, with DS and ypT0 rates reaching 64.4% and 20% for good-risk and 64.5% and 42% for poor-risk patients, respectively. CONCLUSION: To our knowledge, this is the first study to prospectively use TYMS genotyping to direct neoadjuvant CRT in patients with rectal cancer. High rates of DS and ypT0 were achieved among both risk groups when personalized treatment was based on TYMS genotype. These results are encouraging, and further evaluation of this genotype-based strategy using a randomized study design for locally advanced rectal cancer is warranted.
RCT Entities:
PURPOSE: Downstaging (DS) of rectal cancers is achieved in approximately 45% of patients with neoadjuvant fluorouracil (FU) -based chemoradiotherapy (CRT). Polymorphisms in the thymidylate synthase gene (TYMS) had previously defined two risk groups associated with disparate tumor DS rates (60% v 22%). We conducted a prospective single-institution phase II study using TYMS genotyping to direct neoadjuvant CRT for patients with rectal cancer. PATIENTS AND METHODS: Patients with T3/T4, N0-2, M0-1 rectal adenocarcinoma were evaluated for germline TYMS genotyping. Patients with TYMS *2/*2, *2/*3, or *2/*4 (good risk) were treated with standard chemoradiotherapy using infusional FU at 225 mg/m²/d. Patients with TYMS *3/*3 or *3/*4 (poor risk) were treated with FU/RT plus weekly intravenous irinotecan at 50 mg/m². The primary end point was pathologic DS. Secondary end points included complete tumor response (ypT0), toxicity, recurrence rates, and overall survival. RESULTS: Overall, 135 patients were enrolled, of whom 27.4% (37 of 135) were considered poor risk. The prespecified statistical goals were achieved, with DS and ypT0 rates reaching 64.4% and 20% for good-risk and 64.5% and 42% for poor-risk patients, respectively. CONCLUSION: To our knowledge, this is the first study to prospectively use TYMS genotyping to direct neoadjuvant CRT in patients with rectal cancer. High rates of DS and ypT0 were achieved among both risk groups when personalized treatment was based on TYMS genotype. These results are encouraging, and further evaluation of this genotype-based strategy using a randomized study design for locally advanced rectal cancer is warranted.
Authors: H J Lenz; K D Danenberg; C G Leichman; B Florentine; P G Johnston; S Groshen; L Zhou; Y P Xiong; P V Danenberg; L P Leichman Journal: Clin Cancer Res Date: 1998-05 Impact factor: 12.531
Authors: E Villafranca; Y Okruzhnov; M A Dominguez; J García-Foncillas; I Azinovic; E Martínez; J J Illarramendi; F Arias; R Martínez Monge; E Salgado; S Angeletti; A Brugarolas Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: J J Tjandra; D M Reading; S A McLachlan; I F Gunn; M D Green; S J McLaughlin; J L Millar; J S Pedersen Journal: Dis Colon Rectum Date: 2001-08 Impact factor: 4.585
Authors: T E Read; M S McNevin; E K Gross; H M Whiteford; J L Lewis; G Ratkin; J Picus; E H Birnbaum; J W Fleshman; I J Kodner; R J Myerson Journal: Dis Colon Rectum Date: 2001-04 Impact factor: 4.585
Authors: C G Leichman; H J Lenz; L Leichman; K Danenberg; J Baranda; S Groshen; W Boswell; R Metzger; M Tan; P V Danenberg Journal: J Clin Oncol Date: 1997-10 Impact factor: 44.544
Authors: H J Lenz; C G Leichman; K D Danenberg; P V Danenberg; S Groshen; H Cohen; L Laine; P Crookes; H Silberman; J Baranda; Y Garcia; J Li; L Leichman Journal: J Clin Oncol Date: 1996-01 Impact factor: 44.544
Authors: F R Spitz; G G Giacco; K Hess; L Larry; T A Rich; N Janjan; K R Cleary; J M Skibber Journal: Clin Cancer Res Date: 1997-10 Impact factor: 12.531
Authors: Robert J Myerson; Benjamin Tan; Steven Hunt; Jeffrey Olsen; Elisa Birnbaum; James Fleshman; Feng Gao; Lannis Hall; Ira Kodner; A Craig Lockhart; Matthew Mutch; Michael Naughton; Joel Picus; Caron Rigden; Bashar Safar; Steven Sorscher; Rama Suresh; Andrea Wang-Gillam; Parag Parikh Journal: Int J Radiat Oncol Biol Phys Date: 2014-03-15 Impact factor: 7.038
Authors: Tobias Leibold; Vanessa W Hui; Jinru Shia; Jeannine A Ruby; Elyn R Riedel; José G Guillem Journal: Am J Surg Date: 2014-04-13 Impact factor: 2.565
Authors: Tara E Seery; Argyrios Ziogas; Bruce S Lin; Chuan-Ju G Pan; Michael J Stamos; Jason A Zell Journal: J Gastrointest Surg Date: 2012-12-14 Impact factor: 3.452
Authors: F Thomas; A A Motsinger-Reif; J M Hoskins; A Dvorak; S Roy; A Alyasiri; R J Myerson; J W Fleshman; B R Tan; H L McLeod Journal: Br J Cancer Date: 2011-11-01 Impact factor: 7.640
Authors: A Mirza; M Brown; C McNulty; J Valentine; A Annesley; S Galloway; I Welch; C M West; S Pritchard Journal: Gastroenterol Res Pract Date: 2013-03-03 Impact factor: 2.260